Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16791898 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL18171382 | 0.84 | NPC1 (0.46) | SMN1; SMN2NPC1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL16791914 | 0.84 | NPC1 (0.46) | SMN1; SMN2NPC1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL29253308 | 0.82 | ALDH1A1 (0.41) | SMN1; SMN2L3MBTL1ALDH1A1HPGDKDM4E | |
| SCHEMBL17065127 | 0.77 | KMT2A (0.41) | SMN1; SMN2NPC1L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL29253288 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL31281812 | 0.75 | ALDH1A1 (0.39) | SMN1; SMN2L3MBTL1ALDH1A1HPGDKDM4E | |
| SCHEMBL11210429 | 0.74 | PKM (0.44) | SMN1; SMN2L3MBTL1ALDH1A1HPGDKDM4E | |
| SCHEMBL10934047 | 0.74 | PKM (0.44) | SMN1; SMN2L3MBTL1ALDH1A1HPGDKDM4E | |
| SCHEMBL29253304 | 0.73 | CA2 (0.39) | SMN1; SMN2NPC1RAB9AALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114107-B1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2017-03-23 | — | — | US | claimed |
| US-20160311766-A1 | BICYCLIC ALKYL COMPOUNDS AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2016-10-27 | — | — | US | claimed |
| EP-3114107-B1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10654812-B2 | Propellane derivates and synthesis | RECURIUM IP HOLDINGS LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10189780-B2 | Bicyclic alkyl compounds and synthesis | Zeno Royalties & Milestones, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20160311766-A1 | BICYCLIC ALKYL COMPOUNDS AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2016-10-27 | — | — | US | disclosed |
| US-20160311766-A1 | BICYCLIC ALKYL COMPOUNDS AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | PDHA1, PDHA2, DHPS | SMN1; SMN2 2460/4885NPC1 1984/4885L3MBTL1 4755/4885 |
| US-20160311766-A1 | BICYCLIC ALKYL COMPOUNDS AND SYNTHESIS | AP1M1, CYP1B1, CYP2C9 | SMN1; SMN2 2977/4885NPC1 311/4885L3MBTL1 4515/4885 |
| US-10654812-B2 | Propellane derivates and synthesis | PDHA1, PDHA2, DHPS | SMN1; SMN2 2460/4885NPC1 1984/4885L3MBTL1 4755/4885 |
| US-10189780-B2 | Bicyclic alkyl compounds and synthesis | AP1M1, CYP1B1, CYP2C9 | SMN1; SMN2 2977/4885NPC1 311/4885L3MBTL1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.